Trusted expertise

We connect each company to helpful resources, and to mentors and advisors with successful track records in their respective fields.

Mentors

Our mentor network consists of successful entrepreneurs, senior industry executives, key opinion leaders, and investors. Mentors develop close relationships with their matched companies, providing strategic guidance, establishing helpful connections, and working hands-on with the team to accomplish important milestones that we define together.

Anil Trindade
Anil Trindade
Read Bio
XDr. Trindade hails from Princeton Junction, NJ. He received his undergraduate degree in Biochemistry at Lehigh University in 2001. He completed his medical education at Duke University School of Medicine and pursued an Internal Medicine residency at The Johns Hopkins Hospital. He completed his fellowship in Pulmonary and Critical Care Medicine at the Harvard combined Program at Massachusetts General Hospital, Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center. Dr. Trindade initially worked in the lab of Elizabeth Henske to identify a role for microRNA in the pathogenesis of Lymphangioleiomyomatosis and Tuberous Sclerosis Complex. He then joined the faculty at New York Presbyterian Hospital, Columbia University Medical Center, where he gained expertise in managing patients with end-stage lung disease, including those requiring extracorporeal life support and lung transplantation. He moved back to Boston and is currently a faculty member at Brigham and Women’s Hospital and Harvard Medical School. Dr. Trindade’s primary clinical interest is in caring for lung transplant patients. He also practices critical care medicine and is a part of the medical extracorporeal life support team. He is involved in clinical research projects focused on improving outcomes for lung transplant recipients.
Michael Beatrice
Michael Beatrice
Read Bio
XWith 38 years of experience in both the public and private sectors working with pharmaceuticals, biologicals, nutritionals, medical devices, diagnostic and biotechnology products, Mike Beatrice, Ph.D brings a wealth of knowledge and experience as a former regulator, scientist and industry executive. Currently head of an independent consulting company , his previous position was president of Validant, a mid-sized global consulting company. Mike also spent 13 years as Corporate Vice President at Abbott Laboratories, focusing on global Quality and Regulatory compliance. The four years prior to Abbott, Beatrice was a Vice President and a General Manager at Quintiles. (a global contract Research organization).  Previous to that, Mike spent 21 years with the at the U.S. Food and Drug Administration and held various executive management positions including four years as the Deputy Director of the Center for Biologics Evaluation and Research (CBER) and Chemistry Division Director in the Office of Generic Drugs, CDER, FDA. His government service was as an officer in the United States Public Health Service, attaining the rank of Rear Admiral (Assistant Surgeon General). Mike served on the Executive Advisory Council of The College of Integrated Science and Technology at James Madison University, the Board of Visitors at the University of Maryland, School of Pharmacy, The Deans Advisory Council of the University of New Mexico, College of Pharmacy, and as a Visiting Professor at University College, London. He is a charter member of the Food and Drug Administration Alumni Association, and an active member of the Association of Food and Drug Officials. Beatrice earned a bachelor's degree in pharmacy from the University of New Mexico, Albuquerque, and a master's degree in pharmacy from the University of Oklahoma, Norman, and a Ph.D. in pharmaceutics from the University of Maryland in Baltimore (2001).
Edward E. Berger
Edward E. Berger
Read Bio
XA senior healthcare executive with more than 30 years of experience in life science and medical technology reimbursement analysis, planning, and advocacy, Ed Berger founded Larchmont Strategic Advisors in 2005 to help early stage companies deal effectively with the strategic challenges and opportunities posed by the rapidly evolving healthcare regulatory and policy environment. Building upon the knowledge and experience gained as a member of the management teams of such companies as Fresenius Medical Care, Thermo Cardiosystems, and ABIOMED, Dr. Berger has provided reimbursement analysis and strategy development consultation to a variety of clients developing new technologies in fields including mechanical circulatory support, orthopedics, neural monitoring and neuromodulation, gastrointestinal surgery, severe pulmonary dysfunction, nuclear medicine, diagnostic imaging, clinical laboratory testing, and personalized medicine. In addition to reimbursement-related services and public policy analysis and advocacy, his areas of expertise include media relations, investor relations, research ethics and patient protection, and corporate compliance programs.
Michael Bogenstaetter
Michael Bogenstaetter
Read Bio
X

Michael Bogenstaetter has over 15 years experience in Biopharma R&D and commercialization of innovative therapies having worked in different leadership roles with companies such as Johnson & Johnson, Novartis and Sanofi and having advised leading Biopharma organizations as member of the Health Care practice of The Boston Consulting Group. Currently, Michael is an independent management consultant in the Life Sciences area.

Michael holds a Ph.D. in organic chemistry from University of Munich and a full time MBA from London Business School.

Charlie Cameron
Charlie Cameron
Read Bio
X

Charlie has over 20 years of management consulting, business development, and investing experience in more than 40 countries. He is SVP, Strategy, at Cooley LLP, a global law firm that has extensive experience working with life science and tech companies and venture funds. Charlie’s experience ranges from working on strategy with Fortune 500 companies, to counseling emerging technology and life science companies, to venture investing. In addition, he mentors emerging companies and has been a judge for business plan competitions in the US and in Europe. He co-founded the Hub Angel Investment Group which is now on its 5th fund. He works with entrepreneurs and innovators in the US and Europe, and especially with German companies. Charlie has built a global network of entrepreneurs, investors, innovators, and others. He is a frequent speaker, judge and panelist related to venture capital and entrepreneurship. In addition, he is VP and a board member of the German-American Business Council, Boston, advisory board member of the Charite Entrepreneurship Summit, board member of Hub Angels and an advisory member of the Technology Capital Network. He has an MBA, MPH, and BA, Economics – honors.

Philip Christian
Philip Christian
Read Bio
XPhilip Christian, MD, ASCP, ASEM Fellow, American Board of Medical Quality American Society of Clinical Pathology American Society of Emergency Physicians Phil Christian is a successful physician, healthcare executive, serial entrepreneur, and angel investor. Clinically trained in Emergency Medicine and Primary Care, Dr. Christian served as VP and Physician Executive for Bravo Health, the mid-1990’s, venture backed start-up that established the national model for risk-bearing provider groups, and was a progenitor of evidence-based medical practice and personalized healthcare. The company’s $540M acquisition was a testament to the validity and scalability of the clinical model designed, authored, implemented, and managed under “drPhil’s” guidance. His additional professional activities have included medical directorships at some of country’s most prominent healthcare organizations, including: Blue Cross, UnitedHealthcare, Charter Health Plan, Bon Secours Health System, and HCR ManorCare. As a Wharton Fellow, he became actively engaged in mentoring start-ups in digital health innovation, and served a tenure as Managing Director of Health at Dreamit Ventures, a Forbes Top 10 Venture Accelerator based in Philadelphia, PA. Among his current professional activities, he serves as Chief Medical Officer of Florida-based American Health Associates, the largest clinical diagnostic laboratory serving long-term care facilities in the United States. He holds Advisory, Board, and consulting positions with Fortune 100 healthcare companies and healthcare start-ups, and consults with some of the country's premier health corporations, accountable care organizations, digital health accelerators, insurers, and centers of health innovation, including: 500 Start-ups, StartUp Bootcamp, SXSW, Louisville Tech Summit, Merck Innovation, AARP, U.S. Dept. of Navy Innovation, Innova Health Systems, Baptist Health System, Johns Hopkins Medicine, Texas Children’s Medical Center, Catholic Health Initiative, Blue Cross/Blue Shield, Kaiser Permanente, and UnitedHealth/Optum. He holds a consulting portfolio of Silicon Valley Venture Capital and Private Equity Firms focused on digital health innovation, and maintains active clinical affiliations with healthcare institutions in Florida, Georgia, Maryland and Illinois. Dr. Christian has participated in medical missions in underserved countries across the globe; volunteers and fundraises for multiple charitable organizations; is a widely sought-after healthcare thought leader, and frequent speaker and panelist at international health innovation forums. An abbreviated list of certifications and memberships include: American College of Physician Executives, American College of Healthcare Executives, American College of Medical Practice Executives, American Society of Emergency Medicine, National Association of Managed Care Physicians, National Association of Health Services Executives, and The Society of Physician Entrepreneurs.
Jason Coloma
Jason Coloma
Read Bio
XJason is an Entrepreneur-In-Residence at Third Rock Ventures, a life science venture capital firm based in Boston MA and San Francisco CA. At Third Rock, Jason focuses on new company formation and business development across the portfolio. Prior to joining Third Rock, Jason was the senior vice president and chief business officer at Corvus Pharmaceuticals where he was responsible for corporate development, investor relations, and corporate communications. At Corvus, Jason established several partnerships with academic investigators and industry collaborators. From 2008-2016, Dr. Coloma has worked in senior leadership positions related to business and commercial development at Roche Diagnostics and then Roche/Genentech. Most recently, he led a team of business development professionals, business analysts, and competitive intelligence experts charged with augmenting Roche Pharma’s drug discovery and oncology business efforts where he facilitated the closing of a number of deals including Foundation Medicine, Blueprint Medicines, sQz Therapeutics, Tensha Therapeutics, C4 Therapeutics, and Pieris Pharmaceuticals. Before joining Roche, Jason was a consultant in the life sciences practice at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. He also worked in finance at Amgen and in research at the University of California, San Francisco and Cytokinetics. Dr. Coloma earned his B.S. in molecular biology from the University of San Francisco. He received his M.P.H./Ph.D. in Infectious Diseases and Immunity from the University of California, Berkeley and his M.B.A. from the Tuck School of Business at Dartmouth.
David Deems
David Deems
Read Bio
XDavid Deems is a senior executive with a proven ability to commercialize and successfully launch novel technology products for the life sciences and diagnostic markets. During his career, he has developed and launched over 100 new products, in regulated and research markets, and for large public and small venture backed companies. Currently, Mr. Deems serves as the President and CEO of Cellaria, LLC, a biotech company, based in Cambridge, MA, that is focused on the creation of patient-specific models for drug screening, and studying the biology of disease. Previously, Mr. Deems was President and CEO of Xceed Molecular (now part of Axela), a Canadian company with a novel gene expression platform used by clinical laboratories for testing novel biomarkers. David joined Xceed from Predicant Biosciences, an early-stage proteomics company working to identify protein patterns in blood for the early detection of cancer, where he was responsible for managing Predicant’s product and commercial development efforts. Prior to Predicant, David held senior management positions with several companies focused on bringing novel products successfully into the marketplace. He served as Vice President of Product Development at EXACT Sciences; CEO of Union Biometrica prior to that company’s acquisition by Harvard Biosciences; and Vice President at BD Biosciences, a division of Becton, Dickinson and Company. He holds a Bachelor’s Degree from Boston University.
Jens Eckstein
Jens Eckstein
Read Bio
XJens Eckstein is president of SR One, the corporate venture capital arm of GlaxoSmithKline. He joined SR One from TVM Capital where he was last a venture partner, entrepreneur-in-residence and appointed CEO and president of SelectX Pharmaceuticals. Prior to that, he was a general partner in TVM’s Boston life sciences practice where he focused on earlier-stage investments. Jens was the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company. Prior to joining TVM Capital, he led drug discovery programs at Enanta Pharmaceuticals, Inc. and Mitotix, Inc. Jens is currently chairman of the board of directors of Thrasos Therapeutics, and a director at Palleon Therapeutics, Decibel Therapeutics, ZappRx, Gladius Pharmaceuticals and BioHealth Innovation (BHI). He was previously a member of the board of directors for Alios Biosciences, CoNCERT Pharmaceuticals, Enanta Pharmaceuticals, SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an advisor and board observer to Sirtris Pharmaceuticals. He is the author of multiple scientific publications and holds several issued and pending patents. As a Kauffman Fellow and angel investor Jens enjoys mentoring young entrepreneurs. Jens lives with his family in Cambridge, MA.
Colin Foster
Colin Foster
Read Bio
XColin has thirty years of experience as a public and private life science company Chairman, Executive Chairman, Board Member, CEO, and entrepreneur with leadership experience across the R&D-commercial continuum in therapeutics, diagnostics, and medical devices. He has led multi-billion-dollar, midsized, small, and start-up life science companies in the USA, Canada, United Kingdom/Ireland, and Israel. He began his career in pharmaceutical marketing & sales ultimately becoming President & CEO of Bayer Pharmaceuticals North America, following which he co-founded and was CEO of Optherion Inc, a venture-backed biotechnology company. Subsequently, he was Executive Chair of Ivenix Inc, a medical device company, President & CEO of Bioblast Pharma, a public biotechnology company, and founder of iSci Management, a strategic advisory firm. Colin has a B.Sc. in Zoology and Microbiology from the University of Toronto, an M.B.A. from the Ivy School of Business, Western University, and his Canadian Securities Certificate.
Greg Dombal
Greg Dombal
Read Bio
XGreg joined Halloran Consulting Group in 2007. He focuses on helping emerging companies navigate challenges in product development while establishing appropriate clinical, regulatory, and compliance structures. Greg represents clients to worldwide regulatory agencies and routinely functions as an on-demand Head of Regulatory, Clinical, or Development. Greg pairs over 25 years’ experience in worldwide regulatory affairs, quality assurance and clinical development with a willingness to challenge conventional, conservative approaches and find the best solution for each company and their products. Before joining Halloran, Greg was responsible for the regulatory, quality assurance, and clinical groups at ArQule. At its peak, the programs he was responsible for encompassed 17 clinical studies with annual budgets in excess of $25 million. Over his career, Greg has successfully filed over 45 clinical trial applications (IND, IDE or equivalent), attended over 75 regulatory agency meetings, presented to multiple Advisory Committees and helped companies respond to Warning Letters, 522 Orders, and Clinical Hold notices. He has obtained Orphan Drug designation and/or Fast Track designation for fifteen individual products, successfully negotiated multiple Special Protocol Agreements, and has extensive involvement with NDA/MAA submissions resulting in multiple product approvals.

Greg holds a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill. He is also a certified PROSCI change management professional from Colorado State University. He is involved with many non-profit organizations; as an advisor to the Fit Girls Foundation a 501(c)(3) building strong, brave and fit young women; as a past president of Marblehead Youth Baseball, and was a founding board member of the TriROK Foundation a 501(c)(3) dedicated to eliminating childhood obesity.
Andrea Jackson
Andrea Jackson
Read Bio
XAndrea Jackson, is a passionate and commercial minded executive in life sciences and technology with over 11+ years of life science experience. Andrea's experience centers on strategic and operational leadership roles at Millipore, PerkinElmer and as a Independent Advisor where she has launched a portfolio of instruments, software and services focused into the lab market. Andrea currently serves as a Director for the Boston Chapter of Founder Institute, an accelerator focused on enabling pre-seed Founders to start successful companies. Prior to working in Boston’s startup community she was part of JPMorgan’s Healthcare Investment banking team in New York, NY. Andrea holds a BA in Economics with a minor in Biology from Washington University in St. Louis and an MBA from Northwestern’s Kellogg School of Management.
Jacqueline Thong
Jacqueline Thong
Read Bio
X
Jacqueline has over 15 years of experience in software and health IT, in roles ranging from sales and marketing to program and product management. She is now Senior Director, Product at Docent Health, a Bessemer, NEA and Maverick Ventures-funded startup working on improving patient experience for hospitals and health systems. Jacqueline was founder of Klio Health, a MassChallenge 2012 winner which successfully launched a series of patient engagement and care coordination applications. Prior to founding Klio Health, Jacqueline was an early member of CRF Health, one of the leading providers of electronic patient diary systems for the clinical trials industry.
 
Originally from Vancouver, B.C., Jacqueline holds an Bachelor's in Marketing and Information Systems from the University of British Columbia and an MBA from INSEAD.
Karsten Bahlmann
Karsten Bahlmann
Read Bio
XKarsten has a depth of experience in research & development, commercialization and entrepreneurship in the science tools, medical instrumentation and digital heath sectors. Karsten is a co-founder of TissueVision Inc., a leading-edge provider of pre-clinical tissue imaging platforms and currently head of commercialization of Abberior, leader in Nanoscopy for applications in Neuro-Science, Cancer and Cell-Biology. Further, he worked in external innovation for Siemens Healthcare focusing on digital health.

Karsten was a post-doctoral researcher at the Department of Biological Engineering at MIT and holds a Ph.D. in Physics from the Max-Planck-Institute for Biophysical Chemistry and an MBA from MIT Sloan School of Management.
Ali Khademhosseini
Ali Khademhosseini
Read Bio
X

Ali Khademhosseini is Professor of Medicine at Harvard Medical School and Director of the Biomaterials Innovation Research Center at Brigham and Women’s Hospital. He is also a faculty at the Harvard-MIT Division of Health Sciences and Technology as well as an Associate Faculty at the Wyss Institute for Biologically Inspired Engineering and a Junior PI at Japan’s World Premier International-Advanced Institute for Materials Research at Tohoku University where he directs a satellite laboratory. He is recognized as a leader in combining micro- and nano-engineering approaches with advanced biomaterials for regenerative medicine applications.  In particular, his laboratory has pioneered numerous technologies and materials for controlling the architecture and function of engineered vascularized tissues. He has authored over 450 journal papers (H-index = 86, ~27,000 citations) and 50 books/chapters. In addition, he has delivered 300+ invited/keynote lectures. Dr. Khademhosseini’s interdisciplinary research has been recognized by over 40 major national and international awards. He is a recipient of the Presidential Early Career Award for Scientists and Engineers, the highest honor given by the US government for early career investigators. In 2011, he received the Pioneers of Miniaturization Prize from the Royal Society of Chemistry (RSC) for his contribution to microscale tissue engineering and microfluidics. In 2016, he received the Sr. Scientist Award of Tissue Engineering and Regenerative Medicine Society -Americas Chapter (TERMIS-AM) and in 2017 he received the Clemson Award of the Society for Biomaterials. He is also a fellow of the American Institute of Medical and Biological Engineering (AIMBE), Biomedical Engineering Society (BMES), Royal Society of Chemistry (RSC), Fellow of the Biomaterials Sciences and Engineering (FBSE) and American Association for the Advancement of Science (AAAS). Currently he serves on the editorial board of numerous leading journals as well as an Associate Editor for ACS Nano (IF: 12) and a permanent member of NIH BTSS study section. He received his Ph.D. in bioengineering from MIT (2005), and MASc (2001) and BASc (1999) degrees from University of Toronto both in chemical engineering. Read more at: http://www.tissueeng.net/

Thomas Kiessling
Thomas Kiessling
Read Bio
X

Thomas is a technology entrepreneur with 25 years of experience in product and business development in software, hardware, and online consumer products.

Thomas was the CTO / CIO of Securitas Direct, a Bain Capital & Hellman & Friedman company until the end of 2015. Securitas Direct is a private-equity owned supplier of home alarms and connected services for protected homes, sold to Hellman & Friedman in October 2015. Prior to this position Thomas was Chief Product and Innovation Officer for Deutsche Telekom / T Mobile group. Thomas has also worked in CTO / product development roles for bwin Interactive Entertainment AG, Amadeus, and GlobalOne HQ, managing growth businesses and bringing transformational change.

Thomas holds an MA in Economics and was a Fulbright Scholar at the American University, Washington D.C. He also earned a Master in Telecommunications Network Engineering in Paris, France before receiving his Ph.D. in Telecommunications Economics from University of Stuttgart, Germany.

Steve Laken
Steve Laken
Read Bio
XDr. Laken is a pioneer in the biotechnology field with a rich history of forging breakthroughs in molecular testing and product development, clinical studies, and brain-based lie detection. He holds four patents in detecting and testing a familial genetic mutation that causes colorectal cancer, and two in measuring and testing brain activity for lie detection. The American Cancer Society and the American Society of Clinical Oncologists now recommend genetic testing based on his work in the latter patents.
Qi Li
XQi Li, M.D., M.B.A., is a successful healthcare innovator with extensive experience in product inception, research, and global business development. Dr. Li is a board member of Hacking Medicine Institute at MIT. Dr. Li holds the position of director of product innovation at InterSystems in charge of the global clinical product innovation. Dr. Li has held various product leadership roles at Harris Healthcare, Partners Healthcare, and several startup companies in healthcare IT. Previously, as the key person driving the Harris Healthcare global product strategy and sales effort, Dr. Li led the product positioning and market entry efforts in the UK and China. At Partners HealthCare in Boston, Dr. Li led the internal development of the Longitudinal Medical Record (LMR) adopted enterprise-wide by 7,000-plus physician users at all primary care and specialty clinics. Dr. Li consulted for Partners Medical International and taught in the China Initiative at Harvard School of Public Health. Dr. Li advises startups and innovation centers globally. Dr. Li earned his combined M.D. and M.B.A. degrees from Tufts University School of Medicine in Boston, MA and a bachelor’s degree from University of Southern Maine. Dr. Li also attended Shanghai Jiaotong University before moving to US in 1991.
Michael McGrail
Michael McGrail
Read Bio
X

Michael J. McGrail is a partner in the Cooley LLP Business department and a member of the law Firm’s Mergers & Acquisitions, Medical Devices, Venture Capital Financings and International practice groups. He joined the Firm in 2007 and is resident in the Boston office. Mr. McGrail’s practice includes the representation of company and investor clients in a full range of corporate legal projects, including mergers and acquisitions, private financings, corporate partnerships and technology licensing. He counsels companies and investors in many industries, with a particular focus on medical devices and life sciences. Mr. McGrail is fluent in German, and a significant portion of his practice is devoted to international transactions.

Prior to attending law school, Mr. McGrail served as the Head of Regulatory Affairs at a German manufacturer of medical devices. Before joining Cooley, Mr. McGrail was an associate in the Medical Device Practice at Hogan & Hartson in Washington, DC, with a focus on commercial, licensing and FDA regulatory issues.

Mr. McGrail earned his JD from Boston College Law School, graduating cum laude, in 2001. He earned his BA from Northeastern University, graduating magna cum laude, in 1993.

Mr. McGrail has been selected as a Massachusetts Super Lawyers “Rising Star” each year since 2009. He is admitted to practice in Massachusetts and the District of Columbia.

Michael J. Nowak
Michael J. Nowak
Read Bio
XMichael J. Nowak, Ph.D., Managing Partner, Nowak Ventures, LLC, is an experienced healthcare and high-tech investor in small cap public and venture-backed private companies. He is Managing Partner of his own consulting and advisory firm and has prior experience with healthcare- and life sciences-focused investment funds, family offices and boutique investment banks. He was previously a Managing Director and Head of Healthcare Investments for the multinational billion-dollar hedge fund Yorkville Advisors. Before that he led investments and sat on numerous Boards of Directors while a General Partner at the leading billion-dollar Euro-U.S. venture capital fund TVM Capital. He was also a corporate venture capitalist and business development executive at Xerox PARC in Palo Alto, where he was CEO of two startups, a strategic management consultant and Vice President at McKinsey & Co., and a Program Manager at the Advanced Technology Program, National Institute of Standards and Technology, U.S. Department of Commerce. Dr. Nowak earned an MBA from the Wharton School at the University of Pennsylvania and a Ph.D. in Physics from the University of California, Santa Barbara. He worked as a post-doctoral scientist at Bell Labs (Bellcore), Princeton University, and at the CEA research labs in Saclay and the University of Paris VI (Jussieu) in France. He received his B.A. in Physics from Cornell University in Ithaca, NY, where he was a College Scholar.
Pamela Mason
Pamela Mason
Read Bio
XPam leads Mason & Mason’s Innovation Practice, specializing in coverages for life science and technology firms as well as the venture, angel and private equity firms that fund them. Because of her strong technical understanding of the insurance products that facilitate risk transfer, Pam’s focus with her clients centers on risk assessment. She has extensive experience with complex litigation, including securities fraud and other shareholder rights matters, bankruptcy matters, M&A indemnity claims, and employment actions.

Pam frequently lectures and writes on risk management and insurance topics. She has spoken at Venture and Angel Group association meetings at national and local venues. Pam’s articles and commentary have appeared in Venture Capital Journal, Red Herring, Bloomberg and other publications. Prior to joining Mason & Mason, Pam was a Senior Vice President of Marsh, Inc., a global insurance broker, where she led the company’s regional FINPRO management liability practice.

Pam is a Certified Insurance Counselor and an Accredited Advisor in Insurance and received a B.A. degree from the University of Vermont.
Markus Peters
Markus Peters
Read Bio
X

Markus Peters, PhD has more than 20 years of cross-functional and transcultural leadership experience in the global commercialization of treatments that transform the lives of patients with serious medical conditions. Markus is an Associate Partner at Alacrita LLC based in Cambridge, Massachusetts (USA) and advises Life Science companies on the global commercialization of their therapeutic pipeline assets, with focus on rare (orphan) diseases, oncology and specialty pharmaceuticals. Markus was responsible for over ten global specialty pharmaceutical launches including two ultra-orphan franchises: Soliris aHUS (key growth driver for Alexion) and Kanuma (first commercial product for Synageva). For Wyeth/Pfizer, he built the leading biologic blockbuster ENBREL (>$5B sales) by launching the global franchises of four indications in rheumatology and dermatology, and he was the commercial lead for new product planning of the company’s oncology pipeline.

At Synageva BioPharma, Markus was a key member of the senior team that led the transition from research-based to global commercial biopharmaceutical company, resulting in a successful $8.4B buy out in June 2015, the 4th largest deal in the industry.

Markus’ therapeutic area experience includes rare genetic diseases, oncology, immunology (rheumatology and dermatology), hematology, nephrology, hepatology, endocrinology, anti-infectives and metabolic/cardiovascular. He has extensive operational experience on three continents working on the ground in North America (US), Europe (Germany and UK) and Asia (5 years in Japan; China). He has global strategic, US in-line and new product marketing experience, including co-marketing alliances. He has served as the commercial lead on various business and corporate development projects. Markus hired and led cross-functional launch teams located across global regions. Markus is fluent in 6 languages (incl. English, German, French, Japanese incl. reading / writing, Spanish).

He holds a PhD in Biochemistry from Heinrich-Heine University in Düsseldorf, Germany.

Bill Pignato
Bill Pignato
Read Bio
XBill Pignato is the Founder and Principal of W.J. Pignato & Associates, LLC a Boston based consulting firm specializing in global regulatory affairs strategy, which is focused on in vitro diagnostics, medical devices, companion diagnostics and precision medicine, drug/diagnostics co-development and the regulatory deployment of new technologies. Previously Bill was the Vice President, Global Head of Regulatory Affairs - Companion Diagnostics at Novartis where he led the companion diagnostic regulatory program in support of the company’s novel therapeutics in oncology and general medicine. He previously worked at Genentech, Inc leading the regulatory effort specific to the company’s companion diagnostic initiatives. Bill brings over 30 years of strategic global diagnostic regulatory affairs experience in support of bringing products to market, including working on more than 50 drug/diagnostic co-development programs. Prior positions include Vice President of Regulatory Affairs for EXACT Sciences Corp., an applied genomics company focused on the early detection of colorectal cancer and Vice President of Regulatory Affairs for Valeo Medical. He has also previously held senior regulatory positions at Bayer Diagnostics, Chiron Diagnostics and Ciba-Corning Diagnostics. Bill has been active in numerous FDA/Industry cooperative activities regarding regulatory policy impacting diagnostic devices. He has spoken widely on a number of regulatory issues and challenges associated with commercialization of in vitro diagnostic technologies including personalized medicine, companion diagnostics and drug/diagnostic co-development.
Bill Rhodes
Bill Rhodes
Read Bio
XBill Rhodes is the founder of Third Day Advisors LLC, a management and strategy advisory firm. He currently serves as the Chairman of the Supervisory Board of Curetis NV, as well as being on the Boards of Paramit Corporation and Omega Diagnostics Group plc. In previous years he has been on the Boards of the Silicon Valley Leadership Group, the California Healthcare Institute, BIO, Bionic Sight LLC, Andor Technology plc. Vitagen Inc., Conticare Inc., and the San Jose State University Research Foundation. He was the past Chairman of the Leukemia and Lymphoma Society’s Corporate Cup Challenge and currently is on the Editorial Board of the Journal of Clinical Translational Medicine, and an Adjunct Professor at Fudan University, Shanghai. Bill was with Becton Dickinson and Co., retiring in 2012 as an Executive Officer and Senior Vice President, Global Business Development and Strategy, responsible for corporate strategy and global M&A activities. He also served as BD’s Worldwide President, BD Biosciences. He also formed and managed BD Ventures L.L.C., the corporate venture capital fund operated by BD. Prior to joining BD, he held various senior executive roles in business development and technology, for Pfizer, Johnson and Johnson (Ortho Diagnostics; Ortho Pharmaceutical Corp), Reed and Carnrick (Block Drug Company) and The William James Company. Mr. Rhodes holds an M.S.in International Business from Seton Hall University, and was honored there with the W. Paul Stillman School of Business Leadership Award. He served on the university’s faculty as an adjunct professor. Mr. Rhodes also holds a Bachelor of Science degree in entomology from Cornell University. He is the inventor on 13 U.S. patents and has authored numerous articles in the fields of biomedical product development and healthcare investing.
Richard Piazza
Richard Piazza
Read Bio
XDr. Piazza is a career healthcare executive with 38 years of experience in medical devices as well as the pharmaceutical/biotechnology sectors. Included in this is 33 years in general management positions in both public and private international companies including Ohmeda, Smith & Nephew Pharmaceuticals, Marquest & VitaGen (world’s first bioartifical liver). He has gained a reputation of not only introducing new technologies and driving them to success but recruiting and motivating “world class,” highly focused management teams. In addition to a highly successful business career, Piazza has served on industry association boards & committees (Advamed, Biocomm, BioHouston etc.) and was an industry representative working with the FDA and the Congress to craft the FDA Modernization Act for Medical Devices. His Board experience also includes numerous directorships and Chairman roles in both public and private healthcare companies.

In addition to industry affiliations he remains committed to working with well-known medical pioneers to identify and advance new technologies and acts as an advisor to some of world’s leading institutions. These include MD Anderson Cancer Center, Baylor College of Medicine, University of California San Diego, University of Chicago & Kings College Hospital (London.) He has been a guest Lecturer in Sales & Marketing strategy at numerous Universities including Rice University School of Management, UCLA, University of Wisconsin, CAL Tech-MIT forum, University of British Columbia & University of California San Diego.
Oleg Schmidt-Kittler
Oleg Schmidt-Kittler
Read Bio
X

Oleg is a senior scientist at Blueprint Medicines in Cambridge, MA where he is a member of the clinical development team and provides pharmacodynamics and biomarker support for two phase I clinical trials. In addition, Oleg is part of the Joint Project Team overseeing the companion diagnostics development at Ventana Medical Systems. Prior to Blueprint, Oleg was a lab head in the Target Discovery group at Sanofi and served in the Joint Research Committee of two high profile collaborations with the Belfer Institute for Applied Cancer Science and the Dana Farber Cancer institute, respectively.

Oleg obtained his undergraduate education in microbiology and genetics at Philipps University in Marburg, Germany. He then transitioned to cancer biology and focused his doctoral thesis on the genomic evolution of disseminated tumor cells to further the understanding of metastatic spread in breast cancer at the Ludwig-Maximilians University in Munich.

Oleg received his postdoctoral training at the leading cancer genetics lab of Bert Vogelstein and Kenneth Kinzler at Johns Hopkins University in Baltimore, MD, where he was part of the discovery of PI3Kα mutations and contributed to the biochemical and biophysical understanding of the aberrant enzyme activation. He also received a degree in Business Administration during his time there.

Gretchen Schweitzer
Gretchen Schweitzer
Read Bio
XGretchen is the founder and managing director of Trophic Communications, a strategic communications agency solely focused on the life sciences. For 20+ years she has been working as a strategic communicator in the global biopharmaceutical industry advising companies ranging from early-stage innovators to pharmaceutical leaders. Prior to Trophic, Gretchen built the European office of MacDougall Biomedical Communications as Managing Director. In addition to 4 years on the management team of a Munich-based biotech, her expertise is grounded in her career at Feinstein Kean Healthcare (Boston) where she oversaw the entire Corporate Practice, advising over 50 biotechnology and pharmaceutical clients.
Fikadu Tafesse
Fikadu Tafesse
Read Bio
XDr. Tafesse is an Assistant Professor at Oregon Health & Science University (OHSU) in the Department of Molecular Microbiology & Immunology. Dr. Tafesse’s lab focuses on identifying and characterizing the host factors that are used by pathogens to secure invasion, persistence, and propagation. His team is especially interested in studying the role of cellular lipids in bacterial and/or viral pathogenesis and their significance on innate and adaptive immunity. He employs genome-wide genetic screens, various lipidomic analysis techniques and state-of-the-art microscopy and other biochemical tools to define the pathogenesis of M. tuberculosis, HIV and different flaviviruses (Zika, Dengue, West Nile, etc.). Additionally, his work aims to apply novel strategies such as the use of single-domain antibodies/nanobodies not only to unravel the intricate relationships of these pathogens with the host but also to use it as a diagnostic and therapeutics tools. His work is funded through US federal grants (NIH) as well as philanthropies including the Bill & Melinda Gates Foundation. Fikadu received his Master degree from Hannover University (Germany) and his PhD from Utrecht University, The Netherlands. He did his postdoctoral studies at Whitehead Institute for Biomedical Research/Massachusetts Institute of Technology where he was an NWO Rubicon fellow, and worked on the host-pathogen interaction of viruses, fungi, and bacterial toxins. He then served as an Instructor in Medicine, Assistant in Immunology at the Ragon Institute of MGH, Harvard and MIT before he moved his lab to OHSU.
Thomas Collet
Thomas Collet
Read Bio
XThomas is currently President and CEO of Phrixus Pharmaceuticals, Inc. and a co-founder. Prior to Phrixus, Thomas served as President and CEO of four early-stage life science companies which he was instrumental in creating, building and financing. The companies were: Rubicon Genomics, a drug discovery and development tools and biomarker discovery company; Meditrina Pharmaceuticals, a women's health company; ProNAi Therapeutics, a cancer therapeutics company; and Neural Intervention Technologies (NIT), a medical device company developing a therapy for the treatment of hemorrhagic stroke. Previously, he was a general partner at Tullis-Dickerson (TD), where he helped manage a $40 million seed and early stage fund. Prior to his tenure at TD, Thomas was VP, Business Development at Monsanto where he helped start Integrated Protein Technologies, the Company’s internal venture for the production of pharmaceutical proteins in green plants.

Thomas started his career with McKinsey & Company, Inc, where he advised clients in Europe and in the US on strategy and operations in the healthcare and pharmaceutical industries. At McKinsey, his clients were primarily small, technology-focused business units of Fortune 100 companies. Cumulatively, Thomas’s four companies have raised more than $30 million in seed and early-stage capital since 2001 from venture capitalists, pharmaceutical companies, individual investors and government programs.
Brian Wagner
Brian Wagner
Read Bio
XBuilding on his experience in sales and marketing in healthcare, Brian Wagner founded Health Insights Consulting Group to help healthcare and life sciences businesses of all sizes increase revenue through strategic review, market entry implementation, and revenue models focused on sustained growth. Brian has served as Chief Commercial Officer for CAS Medical Systems, Inc. a worldwide entrepreneurial company that designs, manufactures and markets innovative cerebral oximetry medical device technologies. Prior to that, he served as Senior Vice President and Chief Marketing Officer for Philips Imaging Systems, a $7 billion revenue business, where he led worldwide marketing across eight operating divisions.  Brian also held a series of executive management positions at Kimberly-Clark Health Care, now known as Halyard Health, including General Manager of the Global Pain and Temperature Management Division and Vice President of Global Strategic Marketing and Business Development. His experience also includes serving as Vice President and General Manager of Rubbermaid Healthcare, a medical division which he developed and launched, focusing on electronic medical administrative records.  Additionally, he held various sales and marketing management positions of increasing responsibility with Guidant Corporation and Boston Scientific during years of unprecedented growth.  Brian earned his Master's from Harvard University and a Bachelor of Science from Miami University of Ohio.
Mikael Wipperfeld
Mikael Wipperfeld
Read Bio
X

Mikael is a software expert with over 20 years of experience in product marketing and management, international business development, and go-to-market strategy development and execution in the German and US Information Technology space. He has spent the past 10 years focused on supporting European companies entering the US market and US companies entering the DACH market. Mike has experience advising at both the strategic and operational level in terms of how companies look at the respective markets, and what could be viewed as best practices in going to market. He has also held executive and senior management positions in marketing and product management at several organizations including Iron Mountain Digital, SAP, Ascential Software, and Sybase.

Mikael received a BA in Economics from the University of Bonn, and a Master's in Management from Northwestern University.

Derek Young
Derek Young
Read Bio
X

Derek is an entrepreneur and innovator in the healthcare sector. He is a named inventor of over 30 patents with commercial success globally. Derek has successfully co-founded a number of European medical device startup companies including Medtech, Advanced Surgical Concepts and Haptica before spinning into the Royal College of Surgeons (RCSI) in Dublin. While there Derek established a Healthcare Innovation Hub to develop ideas received from clinicians and inventors in Europe and Internationally.

Derek has spear-headed and completed at least 12 Medical Device Licenses deals with key International Healthcare MNC over the last 12 years, completing deals with companies such as Ethicon Endo Surgery, Johnson & Johnson, Covidien, Boston Scientific and CAE Healthcare.

Derek is Founder, CEO and key promoter of i360medical, which is a direct spin out of the Healthcare Innovation Hub that was converted to a for-profit commercial model with the support of the RCSI. I360medical is a European and US based Healthcare Solutions and Medical Device Innovation Company that provides its services to Global Hospital Systems, the Medical Device industry, and clinical communities.

He has gained significant partners and support, and has built an impressive global network of experienced professionals within the medical device and clinical sectors intending to deliver transformational innovation to commercialization change to the international Hospital Systems, Medical Device Industry and Clinical Community.

Derek has a background in Mechanical Engineering, Surgical Innovation and Business Development from the Austin Waldron and Dublin Institute of Technology in Ireland. He also holds a number of board positions on medical device companies and medical research groups at both a national and international level.

Strategic and Innovation Partners

We work with major industry players and service providers to make sure that GALS companies find the right partners and get the best support available.

VC Partners

Community Partners

GALS is part of a wider network of initiatives and organizations that provide advice and support to startups and emerging companies in the U.S. and Germany.